Erasca Inc. (NASDAQ: ERAS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ERASCA INC.

Erasca Inc. (NASDAQ: ERAS)
Listen to this Section


$12.26
-1.0100 ( -7.61% ) 2.3M

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Clinical Trial Pipeline Stages


Drug Name Stage
Naporafenib (pan-RAF inhibitor) w/ trametinibDetailsMelanoma, NRASm melanoma Phase 3
Naporafenib (pan-RAF inhibitor) w/ trametinibDetailsRAS Q61X solid tumors, Solid tumor/s Phase 1b
ERAS-007 w/ encorafenib and cetuximabDetailsCancer, Advanced malignancies, Gastrointestinal stromal tumors, Colorectal cancer , BRAFm Colorectal Cancer Phase 1b
ERAS-801/EGFR inhibitorDetailsCancer, Glioblastoma Phase 1
ERAS-007 + ERAS-601DetailsSolid tumor/s, Cancer Failed
ERAS-601 (SHP2 inhibitor)DetailsSolid tumor/s, Cancer, Head and neck squamous cell carcinoma Failed
ERAS-007DetailsNon-small cell lung carcinoma Failed
Naporafenib (pan-RAF inhibitor) w/ trametinibDetailsSolid tumor/s, RAS Q61X solid tumors Phase 1b

Market Data


Open $12.26
Previous Close $13.27
Volume 2.3M
Market Cap $4.10B
Day Range $12.20 - $13.56
52 Week Range $1.21 - $24.28
Shares Outstanding 310.99M
Change % -7.61%
Net Change ▼ -1.0100
Insider Ownership -0.01%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2021
CountryUnited States
UnderwriterJ.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities, more

Insider Ownership Transactions

Total Amount Purchased: -3,127,441.00

Date Type Amount Purchased Purchaser
2024-06-21 Sale -137142.00 Morris Shannon
2024-06-21 Sale -60000.00 Hambleton Julie
2024-06-21 Sale -60000.00 Casdin Alexander W.
2024-06-21 Sale -60000.00 Bristol James Arthur
2024-06-21 Sale -632759.00 Lim Jonathan E
2024-06-21 Sale -60000.00 Multani Pratik S
2024-06-21 Sale -60000.00 Varney Michael David
2024-06-21 Sale -160082.00 Garner Ebun
2024-06-21 Sale -60000.00 LIU JEAN I
2024-06-21 Sale -60000.00 Start Valerie Denise Harding

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 26, 2025
4 Insider transactions 1 Jun 03, 2025

Latest News


× Before browsing our site, please accept our cookies policy